Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market

Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Size, Market Forecast and Outlook By FMI

The next-generation sequencing (NGS) workflow quality control test kits and instruments market crossed a valuation of USD 550 million in 2025. Revenue is expected to surpass USD 596.2 million in 2026 at a CAGR of 8.4% during the forecast period.

Summary of Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market

• The market is forecast to reach USD 1,335.6 million by 2036.
• The market is expected to grow at a CAGR of 8.4% from 2026 to 2036.
• The market was estimated at USD 550 million in 2025.
• The market is projected to generate approximately USD 740 million in incremental opportunity over the forecast period.
• QC instruments lead by product category with a 58.0% share in 2026.
• Library QC dominates by workflow stage with a 38.0% share in 2026.
• Electrophoresis leads by technology with a 34.0% share in 2026.
• Clinical labs dominate by end use with a 41.0% share in 2026.
• Oncology panels lead by application with a 32.0% share in 2026.
• China is the fastest-growing market at 9.8%, followed by India at 9.5% and South Korea at 8.8%.
• The market is driven by regulatory pressure for validated diagnostic accuracy, rising in-house genetic testing adoption, and the need to prevent failed sequencing runs through precise sample quality control.
• Key companies in the market include Agilent Technologies, Thermo Fisher Scientific, Roche Sequencing Solutions, Bio-Rad Laboratories, QIAGEN, Illumina, and Revvity.

Consistent capital leads the industry sales predicted to accomplish USD 1,335.6 million through 2036 as clinical laboratories mandate documented NGS workflow quality control checkpoints to satisfy strict diagnostic regulatory frameworks. Laboratories remain under steady pressure to identify sample preparation errors before sequencing begins. A flawed sample pushed into a large-scale sequencer can waste thousands of dollars in reagents and delay time-sensitive patient reporting. Dedicated NGS quality control instruments are being adopted to prevent these costly run failures. These automated checkpoints help confirm that NGS sample preparation meets required clinical standards before the sequencing stage starts. Facilities that postpone this investment often continue to absorb higher re-testing costs and face less reliable clinical results.

Processing high volumes of tests forces a permanent shift toward specialized NGS library QC tools. Lab technicians simply cannot rely on slow, manual gel checks when they have to handle hundreds of patient samples every day. To keep the testing line moving quickly and ensure the final data is accurate, facilities must install standardized fragment analysis instruments for NGS.

China is set to lead demand growth, with the market projected to rise at a CAGR of 9.8% through 2036 as regional hospitals continue bringing targeted oncology panels in-house. India follows at 9.5%, supported by expanding genomic research funding across academic centers. South Korea is expected to grow at 8.8% as government-backed precision medicine programs strengthen testing infrastructure. Demand in the United States is projected to increase at a CAGR of 7.9% through 2036. Germany is likely to register 7.4% as diagnostic laboratories align their workflows with IVDR requirements. The United Kingdom is forecast to post a CAGR of 7.1% through 2036, while Japan is expected to record steadier growth at 6.8% over the forecast period.

Segmental Analysis

Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis by Product

Placing capital equipment in a laboratory creates a long-term revenue stream for suppliers through consumable lock-in. Molecular pathology teams support these purchases because automated platforms reduce human error in the validation process. The market is expected to witness the QC instruments category account for 58.0% share in 2026, driven directly by this need for reliable compliance documentation. These machines calculate exact molarity and detect adapter dimers without any manual interpretation. Transitioning to these systems allows clinical facilities to scale their clinical oncology next generation sequencing operations. Equipment brochures rarely mention that these closed systems intentionally restrict third-party reagent compatibility. This architecture forces buyers into predictable, recurring costs, making the initial instrument purchase just the beginning of the financial commitment. Purchasing officers who delay automation face rising labor costs and inconsistent diagnostic reporting.

• Consumable Revenue Capture: Hardware placements lock buyers into proprietary tape and reagent networks. Sourcing managers must accept these recurring costs to maintain instrument warranties and NGS QC software support.
• Workflow Standardization: Automated platforms remove technician variability from sizing calculations. Quality assurance officers gain reproducible metrics required for maintaining clinical laboratory accreditations.
• Data Integration Capability: Modern instruments push results directly into laboratory information systems. Clinical operations teams eliminate manual transcription errors and accelerate overall case turnaround times.

Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis by Workflow Stage

Checking samples right before sequencing determines whether an entire analytical run succeeds or fails. Genomics facility officers prioritize this quantification step because catching a bad preparation early saves thousands of dollars in wasted sequencing reagents. Technicians rely on this specific check to confirm correct adapter ligation and ideal fragment length. Excellent DNA RNA extraction yields mean nothing if the subsequent library construction fails quality standards. Generalist observers miss that many smaller research labs still skip formal library validation to save time, a gamble that routinely ruins data and delays research. In 2026, the Library QC segment is poised to account for 38.0% of market share as clinical operations mandate this step. Operations managers who ignore this mandatory verification consistently report higher overall sequencing costs due to frequent re-testing.

• Adapter Dimer Detection: Validation steps identify unligated adapters that artificially inflate concentration readings. Library preparation technicians avoid loading flow cells with unusable genetic material.
• Multiplexing Normalization: Accurate quantification ensures equal representation of all samples in a pooled run. Sequencing facility operators prevent uneven data output and avoid expensive top-up sequencing requirements.
• Risk Mitigation: Formal validation acts as a financial insurance policy against catastrophic run failures. Buying officers justify genomic risk stratification testing investments through measurable reductions in wasted sequencing reagents.

Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis by Technology

The electrophoresis segment is expected to hold a 34.0% share in 2026 as capillary systems dominate testing facilities by delivering simultaneous sizing and quantification data. Laboratory managers choose this technology because it replaces multiple manual techniques with a single automated process. Fluorometric QC for sequencing libraries provides excellent concentration accuracy, but electrophoresis uniquely visualizes the actual fragment distribution profile necessary for complex theranostic NGS applications. High-throughput facilities depend on this visual confirmation to detect degradation before committing samples to the sequencer. Product brochures emphasize resolution capabilities, but experienced lab officers know the real value lies in the software automatically flagging libraries that fall outside pre-set diagnostic parameters. Facilities attempting to rely entirely on basic fluorometric quantification frequently miss structural library flaws, leading to poor sequencing metrics.

• Fragment Profiling: Capillary systems visualize the exact length distribution of prepared libraries. Molecular technicians detect degradation and primer dimers that standard qPCR library quantification for NGS assays miss completely.
• Throughput Scaling: Automated platforms process up to 96 samples simultaneously without manual intervention. Clinical laboratory officers maintain rapid turnaround times even during peak diagnostic testing periods.
• Software Integration: Proprietary bioinformatics algorithms calculate molarity automatically from the generated electropherograms. Data analysts spend less time formatting results and more time interpreting actual clinical findings.

Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis by End User

Regulatory compliance forces diagnostic facilities to adopt standardized, documented verification procedures for every patient sample. Clinical pathology officers implement NGS quality assurance in clinical labs specifically to satisfy strict IVDR and FDA reporting requirements. Reference laboratories process higher total volumes, but clinical settings face immediate patient-care implications if a sequencing run fails or produces inaccurate data. Executing next generation cancer diagnostics requires absolute certainty regarding sample integrity. The clinical labs category is anticipated to capture 41.0% of the market in 2026 based on these rigid operational mandates. Share figures alone do not reveal that many mid-sized clinical labs operate exactly one automated verification instrument, making device downtime an immediate operational crisis. Hospital purchasing groups failing to secure guaranteed rapid-response service contracts face severe disruptions to their oncology reporting capabilities.

• Compliance Documentation: Automated systems generate locked PDF reports confirming library metrics before sequencing. Quality assurance managers use these records directly during formal laboratory accreditation inspections.
• Operator Training: Intuitive software interfaces reduce the technical expertise required to perform complex validation steps. Laboratory officers maintain operational continuity despite ongoing shortages of highly trained molecular technologists.
• Diagnostic Accuracy: Standardized inputs guarantee consistent sequencer performance across varied patient samples. Clinical oncologists receive reliable multiplex molecular diagnostics reports without unexpected delays caused by re-testing.

Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis by Application

In 2026, oncology panels are projected to secure a 32.0% share because cancer diagnostics demand the highest level of pre-sequencing scrutiny. Molecular oncologists deal primarily with degraded formalin-fixed paraffin-embedded tissue samples, making precise nucleic acid validation essential. Standard molecular diagnostics procedures struggle with these highly fragmented inputs. Technicians must accurately assess the DNA integrity number using specialized oncology NGS QC tools before attempting complex targeted capture protocols. The sheer volume of oncology testing masks the reality that up to twenty percent of clinical biopsy samples fail these initial quality checkpoints, forcing immediate requests for new tissue sections. Pathology departments attempting to process compromised samples without strict verification protocols routinely report false-negative findings, directly impacting patient treatment decisions.

• Integrity Scoring: Specialized algorithms assign objective quality scores to highly degraded tissue samples. Pathology technicians determine immediately whether a biopsy contains sufficient amplifiable material for testing.
• Panel Optimization: Precise input quantification ensures even coverage across hundreds of targeted genomic regions. Bioinformatics teams avoid missing critical tumor mutational burden markers due to low read depth.
• Clinical Turn-around: Rapid validation prevents degraded samples from wasting days in the sequencing queue. Oncology department heads deliver targeted therapy recommendations to patients significantly faster.

Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Drivers, Restraints, and Opportunities

Laboratories face intense pressure to catch sample preparation errors before they reach the sequencer. A failed run on a high-throughput machine immediately burns thousands of dollars in sequencing reagents and delays patient reporting. Purchasing officers buy automated validation instruments specifically as a financial insurance policy against these losses. Running a liquid biopsy workflow at volume requires standardized checkpoints to guarantee sample integrity. Facilities that delay automating these validation steps consistently report higher operating costs due to frequent re-testing.

High initial hardware costs block smaller academic laboratories from adopting automated capillary systems. Research managers see the workflow advantages of dedicated fragment analysis tools but lack the consistent sample volume needed to justify the capital expense. Technicians in these lower-throughput settings must rely on older manual gel methods and basic fluorometers to check their work. Equipment manufacturers try to bridge this gap with reagent rental agreements for their automated molecular diagnostics testing system hardware. These contracts usually require minimum monthly consumable purchases that small research teams cannot guarantee.

• Point-Of-Care Adaptation: Condensing validation technology into smaller footprints allows hospitals to assess samples outside central testing hubs. Clinical officers use these compact tools to speed up rapid pathogen screening directly on the hospital floor.
• Multi-Omics Integration: Equipment builders are developing platforms that quantify nucleic acids and proteins on the same machine. Laboratory managers use these dual-purpose systems to save physical bench space while expanding the types of tests they can perform.
• Infectious Disease Scaling: High-volume pathogen surveillance programs need automated checks to process thousands of samples daily. Public health teams rely on these standardized metrics to run NGS based AMR detection protocols without overwhelming their technical staff.

Regional Analysis

The adoption of quality control tools for sequencing workflows varies significantly across different geographies. Regional growth is largely shaped by local regulatory changes, the expansion of clinical testing infrastructure, and specific funding initiatives for genomic research. Based on regional analysis, Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments market is segmented into Asia Pacific, North America, and Europe across 40 plus countries.

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

Asia Pacific Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis

Regional hospital networks across Asia Pacific are rapidly bringing complex diagnostic testing in-house instead of outsourcing to centralized reference labs. This infrastructure expansion creates immediate demand for automated validation instruments. Technicians in these newly established laboratories require intuitive platforms to master complex genomics workflows quickly. Local equipment manufacturers are also gaining traction by offering lower-priced alternatives to Western systems.

• China: Provincial mandates compel regional hospitals to build independent molecular pathology departments. Demand in China is anticipated to rise at a CAGR of 9.8% through 2036 as these facilities scale up operations. Acquisition agents purchase automated validation platforms to guarantee that their new sequencing installations comply with national diagnostic reporting standards.
• India: Academic research centers are securing substantial funding grants for population-scale sequencing projects. These large-scale initiatives require high-throughput validation tools so facilities can process massive sample cohorts without hiring proportional technical staff. Sales in India for the next-generation sequencing (NGS) workflow quality control test kits and instruments market are expected to increase at a CAGR of 9.5% during the forecast period, reflecting this surge in research capacity.
• South Korea: The sector in South Korea is poised to expand at a CAGR of 8.8% from 2026 to 2036, directly supported by government initiatives funding national precision medicine infrastructure. Tier-one medical centers receive explicit financial backing to expand their diagnostic capabilities. Clinical laboratory officers implement strict automated quality checkpoints to maintain their accreditation under these new federal guidelines.
• Japan: Aging demographic pressures force hospital networks to streamline oncology workflows to manage rising patient volumes. Japan is projected to witness 6.8% CAGR in adoption through 2036 due to this need for speed and accuracy. Pathology departments are replacing manual gel checks with automated platforms to prevent critical reporting delays.

FMI's report includes Australia and Southeast Asian nations. Regional governments actively subsidize the purchase of automated validation equipment to build self-reliant domestic diagnostic networks.

North America Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis

Strict regulatory enforcement dictates capital equipment purchasing behavior across North American laboratories. Diagnostic facility officers must provide unbroken digital audit trails proving sample integrity before generating clinical reports. Operations managers rely on automated validation platforms that push NGS QC standards and controls directly into specialized laboratory information systems. Facilities running point of care molecular diagnostics also require rapid automated sample verification to operate effectively. Supplier competition centers entirely on software capabilities and data integration rather than hardware specifications alone.

• United States: FDA oversight regarding laboratory-developed tests forces clinical officers to implement standardized quality control checkpoints. NGS QC adoption in the United States is set to rise at 7.9% CAGR through 2036 as labs prioritize compliance. Sourcing group select systems offering comprehensive reporting modules over simple analytical performance to meet these strict federal guidelines.

FMI's report includes Canada. Provincial health authorities mandate specific validation criteria before reimbursing hospitals for complex genomic testing procedures.

Europe Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market Analysis

The In Vitro Diagnostic Medical Devices Regulation creates massive compliance hurdles for European sequencing facilities. Laboratory managers are overhauling their legacy validation protocols to meet these strict documentation standards. Upgrading to fully automated quality control platforms has become a legal necessity rather than a simple operational choice. Commercial DNA sequencing services also adopt these tools to guarantee data quality to pharmaceutical clients. Instrument manufacturers who successfully navigated the IVDR certification process early now hold a clear commercial advantage.

• Germany: Germany is anticipated to see sector sales grow at a CAGR of 7.4% over the forecast period because major reference laboratories are consolidating their testing networks. Operations managers standardize all sample validation processes on single-vendor automated platforms. This consolidation simplifies operator training and maintenance scheduling under the new regulatory framework.
• United Kingdom: National Health Service genomic hubs process unprecedented sample volumes following the expansion of centralized clinical testing programs. The United Kingdom sector is expected to register a CAGR of 7.1% from 2026 to 2036 as facilities invest in infrastructure to manage this workload. High-throughput validation instruments allow technical staff to handle the increased demand without sacrificing diagnostic accuracy.

FMI's report includes France, Italy, and Spain. Public health systems in these countries prioritize validation platforms that offer guaranteed reagent supply chains to prevent sudden testing disruptions.

Competitive Aligners for Market Players

Established equipment makers build their platforms to lock in long-term consumable sales from clinical laboratories. Agilent Technologies and Thermo Fisher Scientific are good examples, with automated systems that run on their own testing cartridges. Compatibility with existing companion diagnostics software carries a lot of weight in platform selection. Once a system is validated for patient testing, most hospitals stay with it because switching creates another round of qualification work and disrupts routine lab operations.

Newer suppliers usually try to enter the market with open systems that can work with testing materials from different manufacturers. In transcriptomics technologies, many are designing platforms around the added complexity of RNA sample analysis. FMI analysis suggests that a new supplier only breaks through when the gain in speed or accuracy is clear from the start. Without that, labs have little reason to take on the cost and effort of validating another instrument for clinical use.

Large hospital networks also try to reduce supply risk by keeping more than one brand in operation. Testing volumes are often spread across competing systems so the lab can keep running if one supplier faces delays or backorders. That approach adds some operational complexity, especially as sequencing and spatial omics platform equipment becomes more intricate through 2036. Suppliers will need to support more standardized testing metrics if they want to stay competitive with hospital networks that place a high value on supply continuity.

Key Players in Next-Generation Sequencing (NGS) Workflow Quality Control Test Kits and Instruments Market

• Agilent Technologies
• Thermo Fisher Scientific
• Roche Sequencing Solutions
• Bio-Rad Laboratories
• QIAGEN
• Illumina
• Revvity

Scope of the Report

Source: Future Market Insights (FMI) analysis, based on proprietary forecasting model and primary research

Segments

By Product

• QC instruments
• QC kits
• Reference standards
• QC software

By Workflow Stage

• Library QC
• Extraction QC
• Run QC
• Data QC

By Technology

• Electrophoresis
• qPCR
• Fluorometry
• Digital PCR
• Bioinformatics

By End User

• Clinical labs
• Reference labs
• Academic centers
• Biopharma
• CROs

By Application

• Oncology panels
• Rare disease
• Infectious disease
• Reproductive health
• Research omics

Regions:

• Asia Pacific
  • India
  • China
  • Japan
  • South Korea
  • Indonesia
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Europe
  • Germany
  • Italy
  • France
  • United Kingdom
  • Spain
  • Benelux
  • Nordics
  • Central & Eastern Europe
  • Rest of Europe
• North America
  • United States
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • United Arab Emirates
  • South Africa
  • Turkey
  • Rest of Middle East & Africa

Bibliography

• Centers for Disease Control and Prevention. (2024). Additional NGS quality materials.
• Maver, A., et al. (2024). Quality assurance for next-generation sequencing diagnostics of rare neurological diseases in the European Reference Network. European Journal of Human Genetics, 32(8), 1014-1021.
• Yu, Y., Hou, W., Liu, Y., Wang, H., Dong, L., Mai, Y., Chen, Q., Li, Z., Sun, S., Yang, J., Cao, Z., Zhang, P., Zi, Y., Liu, R., Gao, J., Zhang, N., Li, J., Ren, L., Jiang, H., Shang, J., Zhu, S., Wang, X., Qing, T., Bao, D., Li, B., Li, B., Suo, C., Pi, Y., Wang, X., Dai, F., Scherer, A., Mattila, P., Han, J., Zhang, L., Jiang, H., Thierry-Mieg, D., Thierry-Mieg, J., Xiao, W., Hong, H., Tong, W., Wang, J., Li, J., Fang, X., Jin, L., Xu, J., Qian, F., Zhang, R., Shi, L., & Zheng, Y. (2024). Quartet RNA reference materials improve the quality of transcriptomic data through ratio-based profiling. Nature Biotechnology, 42(7), 1118-1132.
• Cherney, B., Diaz, A., Chavis, C., Ghattas, C., Evans, D., Arambula, D., et al. (2025). The next-generation sequencing quality initiative and challenges in clinical and public health laboratories. Emerging Infectious Diseases, 31(13), 14-17.
• Matsushita, K., et al. (2025). Importance of EQA/PT for the detection of genetic variants in comprehensive cancer genome testing. Scientific Reports, 15(1), 1036.

This bibliography is provided for reader reference. The full FMI report contains the complete reference list with primary source documentation.

This Report Addresses

• Laboratory officers attempting to eliminate preventable sequencing failures through automated validation platforms.
• Acquisition team comparing proprietary consumable lock-in models across competing quality control instrument manufacturers.
• Molecular pathology managers updating their diagnostic validation workflows to meet strict IVDR and FDA reporting requirements.
• Quality assurance teams struggling to accurately quantify degraded formalin-fixed paraffin-embedded tissue samples using oncology NGS QC tools.
• Clinical operations officers transitioning their technical staff away from manual gel electrophoresis methods.
• Bioinformatics specialists integrating automated molarity calculations directly into laboratory information management systems.
• Regional hospital administrators expanding in-house precision medicine infrastructure across the Asia Pacific testing network.
• Diagnostic facility operators evaluating the hidden financial risks of processing unvalidated clinical sequencing libraries.